Inovio Pharmaceuticals Overview
- Year Founded
-
1983
- Status
-
Public
- Employees
-
134
- Stock Symbol
-
INO
- Investments
-
6
- Share Price
-
$1.88
- (As of Monday Closing)
Inovio Pharmaceuticals General Information
Description
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Contact Information
Website
www.inovio.comCorporate Office
- 660 West Germantown Pike
- Suite 110
- Plymouth Meeting, PA 19462
- United States
Corporate Office
- 660 West Germantown Pike
- Suite 110
- Plymouth Meeting, PA 19462
- United States
Inovio Pharmaceuticals Stock Performance
As of 24-Mar-2025, Inovio Pharmaceuticals’s stock price is $1.88. Its current market cap is $68.9M with 36.7M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.88 | $1.92 | $1.74 - $14.75 | $68.9M | 36.7M | 868K | -$3.95 |
Inovio Pharmaceuticals Financials Summary
As of 31-Dec-2024, Inovio Pharmaceuticals has a trailing 12-month revenue of $218K.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | (6,296) | (6,296) | 1,550 | 139,755 |
| Revenue | 218 | 218 | 832 | 10,262 |
| EBITDA | (108,713) | (108,713) | (138,524) | (275,685) |
| Net Income | (107,254) | (107,254) | (135,117) | (279,818) |
| Total Assets | 113,197 | 113,197 | 170,951 | 348,533 |
| Total Debt | 11,865 | 11,865 | 30,209 | 32,074 |
Inovio Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Inovio Pharmaceuticals Comparisons
Industry
Financing
Details
Inovio Pharmaceuticals Competitors (52)
One of Inovio Pharmaceuticals’s 52 competitors is CureVac, a Formerly VC-backed company based in Tubingen, Germany.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CureVac | Formerly VC-backed | Tubingen, Germany | ||||
| ImmunityBio | Formerly VC-backed | San Diego, CA | ||||
| Dynavax Technologies | Formerly VC-backed | Emeryville, CA | ||||
| Regeneron Pharmaceuticals | Formerly VC-backed | Tarrytown, NY | ||||
| Agenus | Formerly VC-backed | Lexington, MA |
Inovio Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Inovio Pharmaceuticals Patents
Inovio Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240399129-A1 | Kinetic vacuum treatment devices, systems, and methods | Pending | 27-Apr-2023 | ||
| US-20240293528-A1 | Methods of treatment of high-grade squamous intraepithelial lesion (hsil) | Pending | 01-Mar-2023 | ||
| US-20240132971-A1 | Methods of treatment of high-grade squamous intraepithelial lesion (hsil) | Pending | 25-Oct-2022 | ||
| US-20240229152-A9 | Methods of treatment of high-grade squamous intraepithelial lesion (hsil) | Pending | 25-Oct-2022 | ||
| US-20240226265-A9 | Lassa virus vaccine and uses thereof | Pending | 24-Oct-2022 | A61K39/12 |
Inovio Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Inovio Pharmaceuticals Investments & Acquisitions (6)
Inovio Pharmaceuticals’s most recent deal was a Later Stage VC with Geneos Therapeutics for . The deal was made on 21-Mar-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Geneos Therapeutics | 21-Mar-2022 | Later Stage VC | Drug Discovery | ||
| Geneos Therapeutics | 12-Nov-2020 | Early Stage VC | Drug Discovery | ||
| Geneos Therapeutics | 21-Feb-2019 | Early Stage VC | Drug Discovery | ||
| Bioject Medical Technologies | 29-Apr-2016 | Merger/Acquisition | Medical Supplies | ||
| Inovio Biomedical (acquired in 2009) | 01-Jun-2009 | Merger/Acquisition | Biotechnology |
Inovio Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated July, 18, 2023
29.53 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,842
Rank
Percentile
Pharmaceuticals
Industry
of 898
Rank
Percentile
Biotechnology
Subindustry
of 402
Rank
Percentile
Inovio Pharmaceuticals FAQs
-
When was Inovio Pharmaceuticals founded?
Inovio Pharmaceuticals was founded in 1983.
-
Where is Inovio Pharmaceuticals headquartered?
Inovio Pharmaceuticals is headquartered in Plymouth Meeting, PA.
-
What is the size of Inovio Pharmaceuticals?
Inovio Pharmaceuticals has 134 total employees.
-
What industry is Inovio Pharmaceuticals in?
Inovio Pharmaceuticals’s primary industry is Biotechnology.
-
Is Inovio Pharmaceuticals a private or public company?
Inovio Pharmaceuticals is a Public company.
-
What is Inovio Pharmaceuticals’s stock symbol?
The ticker symbol for Inovio Pharmaceuticals is INO.
-
What is the current stock price of Inovio Pharmaceuticals?
As of 24-Mar-2025 the stock price of Inovio Pharmaceuticals is $1.88.
-
What is the current market cap of Inovio Pharmaceuticals?
The current market capitalization of Inovio Pharmaceuticals is $68.9M.
-
What is Inovio Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Inovio Pharmaceuticals is $218K.
-
Who are Inovio Pharmaceuticals’s competitors?
CureVac, ImmunityBio, Dynavax Technologies, Regeneron Pharmaceuticals, and Agenus are some of the 52 competitors of Inovio Pharmaceuticals.
-
What is Inovio Pharmaceuticals’s annual earnings per share (EPS)?
Inovio Pharmaceuticals’s EPS for 12 months was -$3.95.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
